Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference
22 March 2023 - 11:00PM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced that it will present at the H.C. Wainwright
Autoimmune & Inflammatory Disease Virtual Conference.
Management will provide an overview of the company’s experience
and expertise in the autoimmune and inflammatory disease space and
highlight EQ101, a tri-specific cytokine inhibitor that selectively
targets IL-2, IL-9, and IL-15, currently being evaluated in a Phase
2 proof-of-concept clinical study of patients with moderate to
severe alopecia areata. Management will also be available for
one-on-one meetings during the conference.
Conference:
H.C. Wainwright Autoimmune &
Inflammatory Disease Virtual Conference
Location:
Virtual
Date:
Thursday, March 30
Time:
10:30 am Pacific Time | 1:30 pm Eastern
Time
Webcast access will be available on the “Events &
Presentations” page under the Investor Relations tab on the
Company’s website at
https://www.equilliumbio.com/investors/events-and-presentations/default.aspx.
An archived replay of the conference will be available for 90
days.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a tri-specific cytokine
inhibitor that selectively targets IL-2, IL-9, and IL-15; currently
under evaluation in a Phase 2 proof-of-concept clinical study of
patients with alopecia areata. EQ102: a bi-specific cytokine
inhibitor that selectively targets IL-15 and IL-21; currently under
evaluation in a Phase 1 first-in-human clinical study to include
healthy volunteers and celiac disease patients. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and a Phase 1b
clinical study of patients with lupus/lupus nephritis. Equillium
acquired rights to itolizumab through an exclusive partnership with
Biocon Limited and has entered a strategic partnership with Ono
Pharmaceutical Co., Ltd. for the development and commercialization
of itolizumab under an asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
Equillium’s ability to execute its plans and strategies; risks
related to performing clinical studies; and whether the results
from clinical studies will validate and support the safety and
efficacy of Equillium’s product candidates. These and other risks
and uncertainties are described more fully under the caption "Risk
Factors" and elsewhere in Equillium's filings and reports, which
may be accessed for free by visiting the Securities and Exchange
Commission’s website at www.sec.gov
and on Equillium’s website under the heading “Investors.” Investors
should take such risks into account and should not rely on
forward-looking statements when making investment decisions. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Equillium undertakes
no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were
made, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230322005232/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2023 to Apr 2024